Mauricio Nogueira

Dr. Mauricio Nogueira

Faculdade de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Brazil
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2018 in Science
Verified
Journal Article
Closed access
PDF file
CMCameron Myhrvold
Cameron Myhrvold
CFCatherine A. Freije
Catherine A. Freije
JGJonathan S. Gootenberg
Jonathan S. Gootenberg
OAOmar O. Abudayyeh
Omar O. Abudayyeh
HMHayden C. Metsky
Hayden C. Metsky
PSPardis C Sabeti
Pardis C Sabeti
Taking CRISPR technology further: CRISPR techniques are allowing the development of technologies for nucleic acid detection (see the Perspective by Chertow). Taking advantages of the distinctive enzymatic properties of CRISPR enzymes, Gootenberg et al. developed an improved nucleic acid detection technology for multiplexed quantitative and highly sensitive detection, combined with lateral flow for visual readout. Myhrvold et al. added a sample preparation protocol to create a field-deployable viral diagnostic platform for rapid detection of specific strains of pathogens in clinical samples. Cas12a (also known as Cpf1), a type V CRISPR protein, cleaves double-stranded DNA and has been adapted for genome editing. Chen et al. discovered that Cas12a also processes single-stranded DNA threading activity. A technology platform based on this activity detected human papillomavirus in patient samples with high sensitivity. Science , this issue p. 439 , p. 444 , p. 436 ; see also p. 381

4 September 2020 in Science
Verified
Journal Article
Open access
DCDarlan S. Candido
Darlan S. Candido
ICIngra M. Claro
Ingra M. Claro
JJJaqueline de Jesus
Jaqueline de Jesus
William SouzaWilliam Souza
William Souza
FMFilipe Moreira
Filipe Moreira
NFNuno Rodrigues Faria
Nuno Rodrigues Faria
The spread of SARS-CoV-2 in Brazil: Brazil has been hard-hit by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Candido et al. combined genomic and epidemiological analyses to investigate the impact of nonpharmaceutical interventions (NPIs) in the country. By setting up a network of genomic laboratories using harmonized protocols, the researchers found a 29% positive rate for SARS-CoV-2 among collected samples. More than 100 international introductions of SARS-CoV-2 into Brazil were identified, including three clades introduced from Europe that were already well established before the implementation of NPIs and travel bans. The virus spread from urban centers to the rest of the country, along with a 25% increase in the average distance traveled by air passengers before travel bans, despite an overall drop in short-haul travel. Unfortunately, the evidence confirms that current interventions remain insufficient to keep virus transmission under control in Brazil. Science , this issue p. 1255

31 July 2020 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
William SouzaWilliam Souza
William Souza
LBLewis Fletcher Buss
Lewis Fletcher Buss
DCDarlan da Silva Candido
Darlan da Silva Candido
JCJean-Paul Carrera
Jean-Paul Carrera
SLSabrina Li
Sabrina Li
NFNuno Rodrigues Faria
Nuno Rodrigues Faria

8 February 2019 in Science
Verified
Journal Article
Closed access
PDF file
IRIsabel Rodriguez-Barraquer
Isabel Rodriguez-Barraquer
FCFederico Costa
Federico Costa
ENEduardo J. M. Nascimento
Eduardo J. M. Nascimento
Nivison Nery Jr.Nivison Nery Jr.
Nivison Nery Jr.
PCPriscila Mayrelle Da Silva Castanha
Priscila Mayrelle Da Silva Castanha
AKAlbert I. Ko
Albert I. Ko
Zika dynamics in South America: The infection dynamics of Zika virus (ZIKV) are difficult to characterize. Many ZIKV infections are asymptomatic, and the clinical presentation of ZIKV is nonspecific. Rodriguez-Barraqueret al.took advantage of a long-term health study under way in Salvador, Brazil, the epicenter of the recent outbreak in the Americas. They used multiple serological assays, from before and after the emergence of ZIKV in October 2015, to distinguish ZIKV immune responses from those against Dengue virus (DENV). About 73% of the population was attacked by ZIKV. The presence of preexisting antibodies to DENV was associated with less risk of ZIKV infection and fewer symptoms.Science, this issue p.607

1 February 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
EKEsper G. Kallás
Esper G. Kallás
MCMonica A.T. Cintra
Monica A.T. Cintra
JMJosé A. Moreira
José A. Moreira
EPElizabeth G. Patiño
Elizabeth G. Patiño
PBPatricia Emilia Braga
Patricia Emilia Braga
MNMauricio Nogueira
Mauricio Nogueira
Butantan-Dengue Vaccine (Butantan-DV) is an investigational, single-dose, live, attenuated, tetravalent vaccine against dengue disease, but data on its overall efficacy are needed. In an ongoing phase 3, double-blind trial in Brazil, we randomly assigned participants to receive Butantan-DV or placebo, with stratification according to age (2 to 6 years, 7 to 17 years, and 18 to 59 years); 5 years of follow-up is planned. The objectives of the trial were to evaluate overall vaccine efficacy against symptomatic, virologically confirmed dengue of any serotype occurring more than 28 days after vaccination (the primary efficacy end point), regardless of serostatus at baseline, and to describe safety up to day 21 (the primary safety end point). Here, vaccine efficacy was assessed on the basis of 2 years of follow-up for each participant, and safety as solicited vaccine-related adverse events reported up to day 21 after injection. Key secondary objectives were to assess vaccine efficacy among participants according to dengue serostatus at baseline and according to the dengue viral serotype; efficacy according to age was also assessed. Over a 3-year enrollment period, 16,235 participants received either Butantan-DV (10,259 participants) or placebo (5976 participants). The overall 2-year vaccine efficacy was 79.6% (95% confidence interval [CI], 70.0 to 86.3) - 73.6% (95% CI, 57.6 to 83.7) among participants with no evidence of previous dengue exposure and 89.2% (95% CI, 77.6 to 95.6) among those with a history of exposure. Vaccine efficacy was 80.1% (95% CI, 66.0 to 88.4) among participants 2 to 6 years of age, 77.8% (95% CI, 55.6 to 89.6) among those 7 to 17 years of age, and 90.0% (95% CI, 68.2 to 97.5) among those 18 to 59 years of age. Efficacy against DENV-1 was 89.5% (95% CI, 78.7 to 95.0) and against DENV-2 was 69.6% (95% CI, 50.8 to 81.5). DENV-3 and DENV-4 were not detected during the follow-up period. Solicited systemic vaccine- or placebo-related adverse events within 21 days after injection were more common with Butantan-DV than with placebo (58.3% of participants, vs. 45.6%). A single dose of Butantan-DV prevented symptomatic DENV-1 and DENV-2, regardless of dengue serostatus at baseline, through 2 years of follow-up. (Funded by Instituto Butantan and others; DEN-03-IB ClinicalTrials.gov number, NCT02406729, and WHO ICTRP number, U1111-1168-8679.).

1 September 2016 in Virology
Verified
Journal Article
Closed access
BCBruno Carneiro
Bruno Carneiro
MBMariana N. Batista
Mariana N. Batista
ABAna Cláudia S. Braga
Ana Cláudia S. Braga
MNMauricio Nogueira
Mauricio Nogueira
PRPaula Rahal
Paula Rahal